Cargando…

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

BACKGROUND: Maintenance monotherapy with the poly(ADP-ribose) polymerase inhibitor olaparib significantly prolongs progression-free survival over placebo in patients with platinum-sensitive relapsed serous ovarian cancer, with greatest benefit seen in patients with a BRCA1/2 mutation (BRCAm). Preser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ledermann, Jonathan A, Harter, Philipp, Gourley, Charlie, Friedlander, Michael, Vergote, Ignace, Rustin, Gordon, Scott, Clare, Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Fielding, Anitra, Bennett, Bryan, Parry, David, Spencer, Stuart, Mann, Helen, Matulonis, Ursula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129820/ https://www.ncbi.nlm.nih.gov/pubmed/27824811 http://dx.doi.org/10.1038/bjc.2016.348

Ejemplares similares

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
por: Friedlander, Michael, et al.
Publicado: (2018)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks
por: Yu, Kun-Hsing, et al.
Publicado: (2020)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
por: Nakamura, Kohei, et al.
Publicado: (2020)

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
por: Tomar, Tushar, et al.
Publicado: (2017)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients
por: Bartl, Thomas, et al.
Publicado: (2021)

Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
por: Tang, Sangsang, et al.
Publicado: (2022)

Tolerance of Olaparib in a Patient With Unresectable Serous Gynecologic Cancer and End-Stage Renal Disease
por: Goon, Kelsey C, et al.
Publicado: (2023)

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
por: Ruscito, Ilary, et al.
Publicado: (2018)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer
por: Van Nieuwenhuysen, Els, et al.
Publicado: (2019)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
por: Lee, Elizabeth K., et al.
Publicado: (2020)

Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013)

Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau
por: Cao, Yabing, et al.
Publicado: (2019)

Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib
por: Eismann, Julia, et al.
Publicado: (2019)

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
por: Colombo, Nicoletta, et al.
Publicado: (2021)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma
por: Hu, Dianxing, et al.
Publicado: (2022)

High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary
por: Matulonis, Ursula A., et al.
Publicado: (2011)

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2018)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
por: Botrus, Gehan, et al.
Publicado: (2022)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas
por: Arias-Diaz, Andrea Estrella, et al.
Publicado: (2023)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
por: Inoue, Kayo, et al.
Publicado: (2020)

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis
por: Levanon, Keren, et al.
Publicado: (2013)

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
por: Batalini, Felipe, et al.
Publicado: (2022)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3o32b6lfc6i725dqpljpqcn87s